Case number 1:22-cv-01390
Astellas US LLC et al v. Baxter Healthcare Corporation > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 1, 2023 | 12 | STIPULATION of Dismissal by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 05/01/2023) (2) |
| May 1, 2023 | 13 | SO ORDERED, re 12 Stipulation of Dismissal filed by Gilead Sciences, Inc., Astellas Pharma US, Inc., Astellas US LLC. CASE CLOSED. Signed by Judge Colm F. Connolly on 5/1/2023. (kmd) (Entered: 05/01/2023) (2) |
| Apr 14, 2023 | 11 | STIPULATION TO EXTEND TIME for Defendant to answer, move or otherwise respond to Plaintiffs' Complaint to May 1, 2023 - filed by Baxter Healthcare Corporation. (Rovner, Philip) (Entered: 04/14/2023) (2) |
| Mar 16, 2023 | 10 | STIPULATION TO EXTEND TIME for Defendant to answer, move or otherwise respond to Plaintiffs' Complaint to April 17, 2023 - filed by Baxter Healthcare Corporation. (Rovner, Philip) (Entered: 03/16/2023) (2) |
| Jan 12, 2023 | 9 | STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiffs' Complaint to March 17, 2023 - filed by Baxter Healthcare Corporation. (Rovner, Philip) (Entered: 01/12/2023) (2) |
| Nov 15, 2022 | 8 | STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiff's Complaint to January 16, 2023 - filed by Baxter Healthcare Corporation. (Rovner, Philip) (Entered: 11/15/2022) (2) |
| Oct 27, 2022 | 7 | SUMMONS Returned Executed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc..Baxter Healthcare Corporation served on 10/27/2022, answer due 11/17/2022. (Del Dotto, Kelly) (Entered: 10/27/2022) (2) |
| Oct 24, 2022 | 1 | Complaint* (1) |
| Oct 24, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 10/24/2022) (3) |
| Oct 24, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/12/2022. Date of Expiration of Patent: 02/02/2027.Thirty Month Stay Deadline: 3/12/2025. (vfm) (Entered: 10/24/2022) (1) |
| Oct 24, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE 47,301 E ;US 8,524,883. (vfm) (Entered: 10/24/2022) (1) |
| Oct 24, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas US Holding, Inc for Astellas Pharma US, Inc., Astella Pharma Inc. for Astella Pharma US, Inc. Astellas US LLC filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (vfm) (Entered: 10/24/2022) (2) |
| Oct 24, 2022 | 6 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (vfm) (Entered: 10/24/2022) (2) |
